Debrisoquine oxidation phenotype during neuroleptic monotherapy

POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN

A. Mahgoub, L. G. Dring, Jeffrey R. Idle et al. · The Lancet · 1977 · 1.2K citations

Pharmacy, Biochemistry, Pharmacology +6

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

Michel Eichelbaum, N. Spannbrucker, Barbara Steincke et al. · European Journal of Clinical Pharmacology · 1979 · 635 citations

Medicine, Molecular Medicine, Pharmacology +8

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

David A. Evans, A. Mahgoub, T.P. Sloan et al. · Journal of Medical Genetics · 1980 · 540 citations · Full text

Life Sciences, Genetics, Pharmacology +17

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

K. Br�sen, L. F. Gram · European Journal of Clinical Pharmacology · 1989 · 285 citations

Medicine, Toxicology, Molecular Pathology +6

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

T. Inaba, M Jurima, W. A. Mahon et al. · Drug Metabolism and Disposition · 1985 · 180 citations

Medicine, Medicinal Chemistry, Pharmacology +16